T he human ␥-herpesviruses, EBV and Kaposi's sarcomaassociated herpesvirus, are persistent pathogens that establish life-long latency, mainly in B lymphocytes. In immunocompetent individuals, the virus is maintained in a quiescent state through immune mechanisms of control. However, in immunocompromised individuals, for example, as a consequence of posttransplant immunosuppression or AIDS, loss of immune control is associated with the onset of lymphoproliferative disorders and various malignancies. Thus, understanding the immune control of ␥-herpesvirus latency is a major health priority. Immune control of human ␥-herpesviruses is thought to be predominantly mediated by CD8 ϩ T cells (1, 2) , and adoptive immunotherapy with EBV-specific cytotoxic T cells following bone marrow transplantation reduces the risk of developing posttransplant EBV-associated lymphoproliferative disease and lymphomas (3) . In contrast to the well-established role of cell-mediated immunity, little information is available regarding the contribution of Ab to controlling persistent ␥-herpesvirus infection.
Murine ␥-herpesvirus-68 (MHV-68) 3 is a natural pathogen of rodents that provides an easily manipulated small animal model for studying general mechanisms of immune control of ␥-herpesviruses. The virus has significant biological and structural similarities to the human ␥-herpesviruses (4, 5) and is emerging as an important experimental model for studying mechanisms of ␥-herpesvirus-induced pathology and basic mechanisms of immune control of ␥-herpesviruses (6 -10) . Intranasal infection with MHV-68 establishes an acute viral infection in the lungs. Although the lytic virus is rapidly cleared, largely by CD8 ϩ T cells, the virus is thought to disseminate from the lung, and latency is established (11) . Similar to the human ␥-herpesviruses, B cells are a major reservoir of latent virus, although macrophages, dendritic cells and lung epithelial cells can also be latently infected (11) (12) (13) (14) . Both CD4 ϩ T cells and CD8 ϩ T cells are important in the immune control of latency (reviewed in Ref. 9) .
Despite the importance of T cells in controlling MHV-68 infection, T cell depletion of latently infected mice does not result in viral recrudescence, indirectly suggesting a role for virus-specific Ab (11, 15) . Following MHV-68 infection, there is a strong nonspecific Ab response, closely followed by a virus-specific Ab response (16, 17) . The possibility that Abs participate in immune control of the latent stages of infection was supported by experiments showing that T cell depletion of B cell-deficient MT mice, but not control C57BL/6 (B6) mice, allowed viral recrudescence in the lung (11, 18) . The goal of the current studies was to directly assess the contribution of virus-specific Abs in the immune control of latent MHV-68. Because B cells are an important reservoir of latency (12, 14) , and also play an important role in disseminating virus in the host (11) and in controlling reactivation from latency (19) , analysis of Ab-mediated immune control of latency must be conducted in mice with normal B cells, to allow the development of normal reservoirs of latency, but with no anti-viral Abs. We show that CD28-deficient (CD28 Ϫ/Ϫ ) mice provide a suitable model. CD28 is a costimulatory molecule important in T-B collaboration (reviewed in Ref. 20) . CD28 Ϫ/Ϫ mice have normal levels of CD4 ϩ and CD8 ϩ T and B cells (21) , but have deficient humoral immunity (21, 22) . CD28 Ϫ/Ϫ mice have been shown to be capable of controlling some, but not all, viral infections (21) (22) (23) (24) (25) (26) (27) . Our laboratory previously reported that CD28 Ϫ/Ϫ mice established MHV-68 latency in B cells although at reduced levels compared with B6 mice, correlating with decreased numbers of peanut agglutinin (PNA) high germinal center B cells, which we showed to be a preferential reservoir for latency (14) . Therefore, CD28
Ϫ/Ϫ mice provide a relevant model for examining the role of humoral immunity in controlling MHV-68 latency. The current analysis of MHV-68-infected CD28 Ϫ/Ϫ mice showed that the mice controlled the initial lytic infection, established normal reservoirs of latency, including B cells, and exhibited normal longterm immune control of latency, yet had a defective Ab response. Importantly, upon T cell depletion, Ab-deficient CD28 Ϫ/Ϫ mice, but not B6 mice, lost immune control of latency in the lung and spleen, indicated by recrudescence of lytic virus. Prevention of viral recrudescence after passive transfer of immune serum directly demonstrated a role for virus-specific Ab in immune control of MHV-68 latency.
Materials and Methods

Mice
C57BL/6J (B6) and C57BL/6-CD28 tm1Mak (CD28 Ϫ/Ϫ ) (21) mice were bred at the Trudeau Institute (Saranac Lake, NY) or purchased from The Jackson Laboratory (Bar Harbor, ME). Six-to 8-wk-old male and female mice were housed under specific pathogen-free conditions in BL3 containment for the experimental period. All animal procedures in these experiments were approved by the Institutional Animal Care and Use Committee at the Trudeau Institute. CD28
Ϫ/Ϫ mice received sulfamethoxazole and trimethoprim (GensiaSicor Pharmaceuticals, Irvine, CA) treated water throughout the study to prevent opportunistic infection by Pneumocystis carinii (28) .
Virus
MHV-68 (WUMS strain) was obtained from S. Virgin (University of Washington, St. Louis, MO) and propagated in NIH 3T3 cells. Virus titer was determined by plaque assay on NIH 3T3 cells as described (6) . Mice were anesthetized with 2,2,2-tribromoethanol and intranasally infected with 400 PFU of the virus. Control mice were infected with 300 50% egg infectious doses of influenza A virus (A/HKx31), as described (29) .
Immunohistochemistry
Spleens were imbedded in Optimum Cutting Temperature compound (Miles, Elkhart, IN) and snap frozen in liquid nitrogen. Serial sections (6 m) were incubated with anti-mouse B220/CD45RB Ab (RA3-6B2; BD PharMingen, San Diego, CA) or PNA-conjugated with biotin (Vector Laboratories, Birmingham, CA). Subsequently, the sections were incubated with the avidin/biotin peroxidase complex, and then incubated with 3,3Ј-diaminobenzidine substrate (Vector Laboratories). Sections were counterstained with H&E.
Virus-specific Ab assays
Virus-specific Ab titer was determined by ELISA (17) . Sera from naive or influenza virus-infected mice were included as negative controls. Neutralizing activity was determined as described (16) , except dilutions of serum were incubated with 100 PFU MHV-68 for 90 min and were cultured with NIH 3T3 cells for 6 days. The neutralizing titer refers to the highest dilution of serum that reduced the number of plaques by 50%. 
Assays for virus-specific T cells
Infective center assay
Infective center assays were performed as described (32) . Briefly, serial dilutions of splenocytes or lung homogenates were plated onto monolayers of NIH 3T3 cells and overlaid with carboxymethyl cellulose. After 6 days of culture, cells were fixed and stained with Giemsa (Sigma-Aldrich, St. Louis, MO). As this assay measures lytic virus as well as reactivable latent virus, samples were simultaneously assayed after a single freeze/thaw cycle to assess the contribution of lytic virus to the titers. Previous controls have shown that a single freeze/thaw cycle does not result in the loss of lytic virus (33) . Reactivable latent virus levels in individual mice were calculated by subtracting virus levels of the freeze/thaw sample from virus levels of the duplicate untreated sample.
Limiting dilution-nested DNA PCR
Splenocytes were stained with Ab against CD4/CD8-FITC and CD19-PE, (BD PharMingen) and propidium iodide (Sigma-Aldrich). The viable (propidium iodide-low) lymphocyte population was gated and CD19 ϩ cells were FACS-sorted to a purity of Ͼ99%. To determine the frequency of latency in purified B cells, nested PCR was performed on serial dilutions of B cells, and frequencies were determined by Poisson distribution, as described (13, 19, 34) . As controls of nested PCR, 10 4 NIH 3T3 cells/well with and without plasmid DNA containing the MHV-68 ORF50 gene were included in each 96-well PCR assay. As preformed lytic virus was undetectable in the spleens of B6 and CD28 Ϫ/Ϫ mice by infective center assay after day 35 postinfection, genome-positive cells assessed after this time were considered to be latently infected.
In vivo T cell depletion
Mice were injected i.p. with 250 g purified anti-Thy1.2 (30H12), anti-CD4 (GK1.5), anti-CD8 (TIB210), or isotype-matched control Ab (Rat IgG2b, LTF2) from ascites or concentrated culture supernatant at 2-3 day intervals for 14 -21 days, beginning ϳ60 days postinfection. To confirm T cell depletion, splenocytes were stained with anti-CD4 or anti-CD8 Abs or MHV-68 tetramers. The postdepletion levels of CD4 ϩ and CD8 ϩ T cells were Ͻ1% of total spleen cells and virus-specific memory T cells were undetectable.
Passive transfer of immune serum
Immune sera were obtained from MHV-68-infected B6 mice 28 -35 days postinfection. Neutralizing Ab and MHV-68 specific-IgG levels were determined and the protective effect of the immune sera against MHV-68 infection was tested in naive B6 mice (data not shown). CD28
Ϫ/Ϫ and B6 mice were administered 2.5 ml immune sera i.p. in 0.5 ml doses at 8-h intervals, as described (35) . Immune serum from influenza A-infected mice was administered as a control. One day after the final injection of immune sera, in vivo T cell depletion was initiated.
Statistical analysis
ELISA titers of MHV-68-specific Abs were analyzed by the Mann-Whitney Sum test. Significant differences ( p Ͻ 0.05) in the number of virusspecific T cells between CD28 Ϫ/Ϫ and B6 mice were determined by a two-tailed Student's t test.
Results
CD28 Ϫ/Ϫ mice control lytic and latent MHV-68 infection
It has been shown that the costimulatory requirements for antiviral CTL responses depend on the properties of the virus. For example, CD28 Ϫ/Ϫ mice effectively control lymphocytic choriomeningitis virus, but fail to control vesicular stomatitis virus and influenza virus (21) (22) (23) (24) (25) 27) . To determine whether CD28 Ϫ/Ϫ mice could effectively control acute MHV-68 infection, mice were infected intranasally with virus, and lytic viral load in the lung was followed. Although the peak viral titers were higher and the kinetics of clearance were delayed (ϳ2 days) compared with B6 control mice, CD28
Ϫ/Ϫ mice effectively cleared lytic virus (Fig.  1A ). There was no evidence for viral recrudescence in the lung at timepoints up to 150 days postinfection (data not shown).
Analysis of latency by two different methods showed that CD28 Ϫ/Ϫ mice efficiently established and controlled latency. First, we assessed latency by an infective center assay, which is dependent upon the ability of latently infected cells to spontaneously reactivate in vitro when plated on a susceptible cell monolayer. The data showed that latency was controlled comparably in B6 and CD28 Ϫ/Ϫ mice, as the ability of latently infected cells to reactivate fell off rapidly, falling to below the limits of reliable detection after 3-4 wk (Fig. 1B) . As this assay can also detect lytic virus, the inability to detect recrudescent lytic virus at later timepoints is another indication that latency is controlled in the spleens of CD28 Ϫ/Ϫ mice. Second, we determined the frequency of latently infected splenic B cells in the long-term by a limiting dilution/PCR assay. In this assay the frequency of latently infected cells is assessed by the presence of viral genome in the absence of preformed infectious virus (36) . The data show that the reservoirs of long-term latency in splenic B cells in B6 and CD28
Ϫ/Ϫ mice are entirely comparable (Fig. 1C) . Both the infective center and limiting dilution/PCR assays showed that initial levels of latency were reduced ϳ10-fold in CD28
Ϫ/Ϫ mice, as we previously described (14) , likely a consequence of reduced numbers of activated germinal center B cells, which harbor the highest frequency of latency early after infection.
The virus-specific T cell response was also assessed in terms of numbers of virus-specific T cells and IFN-␥ secretion. There were comparable numbers of T cells specific for two MHV-68 MHC class I epitopes, ORF6 487-495 /D b and ORF61 524 -531 /K b , assessed by tetramer staining, in the spleens ( Fig. 2A ) and lungs (data not shown) of MHV-68-infected CD28 Ϫ/Ϫ and control mice. In addition, virus-specific CD4 ϩ and CD8 ϩ T cell effector function was assessed by an IFN-␥ ELISPOT assay (Fig. 2B) . The data show that the virus-specific CD8 ϩ T cell numbers and IFN-␥ responses are relatively normal in the CD28 Ϫ/Ϫ mice. CD4 ϩ T cells from CD28 Ϫ/Ϫ mice were functional, although the magnitude of the IFN-␥ response was reduced at all timepoints measured. Taken together, the clearance of lytic virus, the absence of viral recrudescence, the comparable frequencies of latently infected cells, and the relatively normal numbers and function of virus-specific T cells are consistent with efficient T cell immune control of MHV-68 in CD28 Ϫ/Ϫ mice.
CD28 Ϫ/Ϫ mice do not form germinal centers and have a compromised Ab response following MHV-68 infection
It has been reported that CD28 Ϫ/Ϫ mice do not form germinal centers, due to the absence of T-B interactions (37) . However, because an early feature of MHV-68 infection is activation of both B and T cells (38) , it is formally possible that the virus overcomes the requirement for CD28-mediated T-B interactions in the formation of germinal centers. B and T cell activation appeared to be relatively intact in CD28 Ϫ/Ϫ mice, as our previous analysis showed that splenomegaly and T cell lymphocytosis of the peripheral blood are comparable to that observed in B6 mice (Flaño et al., Ref. 14; data not shown). Therefore, we examined spleen sections for germinal center formation after MHV-68 infection. Although PNA ϩ clusters were found scattered in the splenic red pulp in CD28
Ϫ/Ϫ mice after viral infection (Fig. 3) there was no evidence for the formal architecture of germinal centers. Thus, despite comparable MHV-68-induced activation of both B and T cells, the viral infection did not overcome the inability of CD28 Ϫ/Ϫ mice to form germinal centers.
Analysis of virus-specific Ab formation after MHV-68 infection showed comparable levels of IgM Abs (Fig. 4A) and, despite the absence of germinal center formation in the CD28 Ϫ/Ϫ mice (37), the levels of virus-specific IgG Abs were comparable in B6 and CD28 Ϫ/Ϫ mice when measured 28 days after infection (Fig. 4B) . However, the titers of MHV-68-specific class-switched Abs (Fig.  4B ), but not MHV-68-specific IgM Abs (Fig. 4A) waned rapidly with time in CD28 Ϫ/Ϫ mice, whereas the titers of MHV-68-specific class-switched Abs were sustained at high levels in B6 mice (Fig. 4B) . In addition, the Abs in CD28 Ϫ/Ϫ mice were poorly neutralizing (Fig. 4C) . Thus, the Ab response to MHV-68 is profoundly impaired in CD28 Ϫ/Ϫ mice.
Effect of T cell-depletion on the control of viral latency in the absence of protective humoral immunity
Our findings that CD28 Ϫ/Ϫ mice have normal reservoirs of B cell latency, effective T cell immune control, but defective humoral immunity to MHV-68, confirmed that they are a suitable model for directly examining the contribution of humoral immunity in the control of ␥-herpesvirus latency. Thus, we depleted T cells from MHV-68-infected mice by i.p. injection of anti-Thy1.2 mAb. We initiated T cell depletion ϳ60 days postinfection, at a time when there was no neutralizing Ab (Fig. 4C) , and monitored levels of lytic virus in the lungs and spleens 2 wk later. The analysis showed recrudescence of lytic virus in both the lungs (Fig. 5A) and spleens ( Fig. 5B) of Ab-deficient CD28 Ϫ/Ϫ mice, but not control mice. These data strongly support the possibility that humoral immunity contributes to the control of MHV-68 latency. T cell depletion also resulted in a striking increase in latent virus in the spleens of CD28 Ϫ/Ϫ mice, and to a lesser extent, in the spleens of B6 mice, as determined by the infective center in vitro reactivation assay (Fig. 5C) .
To distinguish the contribution of CD4 ϩ and CD8 ϩ T cells to the immune control of latency in the absence of an effective Ab response, the experiment was repeated using anti-CD4 and/or anti-CD8 Abs for depletion. The data show only low levels of lytic virus in the lung (Fig. 6A) and none in the spleen (Fig. 6B) following depletion of either CD4 ϩ or CD8 ϩ T cells, whereas depletion of both subsets resulted in recrudescence of lytic virus in the lung and spleen of CD28 Ϫ/Ϫ mice. In addition, depletion of both subsets of T cells was also required for loss of control of latently infected spleen cells capable of in vitro reactivation in Ab-deficient mice (Fig. 6C) .
Passive transfer of immune serum prevents recrudescence of lytic virus after T cell depletion of MHV-68-infected CD28
Ϫ/Ϫ mice To directly demonstrate a role for Ab in the immune control of ␥-herpesvirus latency, MHV-68 immune serum was obtained from latently infected B6 mice and passively transferred into CD28
Ϫ/Ϫ mice, just before initiation of the T cell depletion regimen. Influenza A virus-specific immune serum was transferred to a separate cohort of mice as a specificity control. Consistent with a role for Ab in controlling persistent virus, the data show that transfer of MHV-68 immune serum, but not the irrelevant serum, prevented the recrudescence of lytic virus in the lung (Fig. 7A) and spleen ( Fig. 7B ) of T cell-depleted MHV-68-infected CD28 Ϫ/Ϫ mice. Consistent with a role for T cells in controlling reactivation from latency independent of Ab, transfer of immune serum did not prevent the increase of latently infected spleen cells capable of in vitro reactivation (Fig. 7C) . Analysis of the MHV-68-specific Ab titers in CD28 Ϫ/Ϫ mice into which immune serum had been transferred confirmed that the Ab transfer had reconstituted normal levels of MHV-68-specific IgG (Fig. 7D) and that the transferred immune Ϫ/Ϫ mice were significantly different from the virus levels in B6 mice (p Ͻ 0.03). The limit of the detection of this assay is indicated by the dotted lines.
FIGURE 6. Depletion of both CD4
ϩ and CD8 ϩ T cells is necessary for viral recrudescence. Beginning at 60 days after MHV-68 infection of B6 (open symbols) or CD28 Ϫ/Ϫ (closed symbols) mice, subsets of T cells were depleted by in vivo i.p. injection of 250 g anti-CD4 (GK1.5) and/or anti-CD8 (TIB210) Ab in 3-day intervals for 2 wk. Lytic virus in the lung (A), expressed as PFU per lung, was determined by plaque assay, as in Fig. 1A . Levels of lytic virus (B) and reactivable latent virus (C) in the spleens were quantitated by an infective center assay, as in Fig. 1B . The limits of the detection of the assays are indicated by the dotted lines serum restored the neutralizing titers to levels comparable to those of MHV-68-infected B6 mice (Fig. 7E) . These data directly demonstrate a role for humoral immunity in the control of ␥-herpesvirus latency.
Discussion
This report is the first direct demonstration of a role for humoral immunity in control of the persistent phase of ␥-herpesvirus infection. Thus, T cell-depletion of CD28 Ϫ/Ϫ mice with impaired anti-viral Abs, but not control B6 mice with intact humoral immunity, resulted in viral recrudescence in the spleen and lungs. A direct role for protective Abs was demonstrated by the ability of passively transferred immune serum to prevent viral recrudescence in CD28
Ϫ/Ϫ mice after T cell depletion. The data suggest that virus-specific Abs and immune T cells play complementary roles in preventing viral recrudescence, as deficiency in both cellular and humoral immunity was necessary to allow recrudescence of lytic virus. For example, neither T celldepleted B6 mice with intact humoral immunity nor CD28 Ϫ/Ϫ mice with functional T cell immunity but no anti-viral Abs, showed evidence of recrudescent lytic virus. A likely scenario is that T cells prevent reactivation of latently infected cells, and Ab prevents the dissemination of reactivating lytic virus. A similar role for Abs has been previously described for murine CMV, a ␤-herpesvirus (35) . Ab-mediated protection is presumably mediated by direct neutralization, although the current studies do not specifically address the mechanism.
Although both Ab and T cells contributed to the control of recrudescent lytic virus, differences in viral latency were noted in the absence of T cells, whether or not Abs were present. This was indicated by the increased ability of latently infected spleen cells in T cell-depleted mice to reactivate in vitro. In the normal course of infection, latently infected spleen cells reactivate readily in vitro early after the establishment of MHV-68 latency (within 2-3 wk), but long-term latency is not detectable by in vitro reactivation, although the frequency of latently infected cells drops only slightly (6, 19) , suggesting alternative states of latency. The transition is thought to be controlled by CD8 ϩ T cells, which either drive latently infected cells to an altered form of latency, or selectively eliminate cells capable of in vitro reactivation (33) . Thus, there are two possible explanations for the increase in in vitro reactivation from latency in the absence of T cell immunosurveillance observed in the current studies. One possibility is that T cell depletion allows a qualitative change in latency: a "reversion" of pre-existing latently infected cells to a less restricted form of latency more prone to in vitro reactivation. A second possibility is that recent reinfection by recrudescent lytic virus contributes to the increase in the number of latently infected cells capable of in vitro reactivation. The observation that there is an increase in latently infected cells capable of in vitro reactivation in B6 mice with intact humoral immunity that would prevent reinfection supports the first possibility. The higher and more consistent levels of reactivation seen in the CD28
Ϫ/Ϫ mice that lack neutralizing Abs, compared with control mice with intact humoral immunity, is consistent with the second possibility.
B cell-deficient MT mice have been widely used to study immunity in the absence of Abs. However, because B cells are an important reservoir of ␥-herpesvirus latency and play an essential role in the dissemination of latent virus (11, 12, 14, 19) , MT mice are not suitable for analyzing the immune control of ␥-herpesvirus latency because they do not develop normal reservoirs of latency (11, 39) . An important aspect of the current study is that not only was recrudescent lytic virus detectable in the lung as had previously been shown after T cell-depletion of MT mice (11), but recrudescent lytic virus was also detected in the spleens of T celldepleted CD28
Ϫ/Ϫ mice. Presumably virus had reactivated from latently infected epithelial cells in the lungs of MT mice, whereas reactivation in the spleen in the CD28 Ϫ/Ϫ mice was from B cells, as well as other latently infected cell types. The data suggest that there may be cell type-or tissue-specific T cell immune control of persistent virus, as both CD4 ϩ and CD8 ϩ T cells were required to prevent recrudescence in the lung, whereas either CD4 ϩ or CD8 ϩ T cells were sufficient to control reactivation of lytic virus in the spleen. These data reinforce the premise that immune control of persistent ␥-herpesviruses is optimally studied in models with normal B cell latency. The generation of a class-switched virus-specific response in the absence of germinal centers in CD28 Ϫ/Ϫ mice is not entirely unexpected. It has been shown that although germinal centers are a site of isotype switching, they are not essential, as isotype switching occurs largely in the periarteriolar lymphoid sheaths (40) . Affinity maturation has also been shown to occur in the absence of germinal centers (41) . The Ab response after viral infection has also been analyzed in other mouse strains deficient in germinal center formation. For example, lymphotoxin ␣ Ϫ/Ϫ mice showed isotype-switched Abs at day 50 after MHV-68 infection, although the virus neutralizing activity was not assessed (42) . In TNFR Ϫ/Ϫ mice, initially vesicular stomatitis virus-specific Ab induced by live virus was of comparable neutralizing titer to controls, but waned with time (43) . In the current studies, the poor neutralizing and waning Ab response is likely independent of the absence of germinal centers per se, but is a consequence of impaired CD4 ϩ T cell help. Although Ab responses against proteins normally require mice at 50 days after MHV-68 infection in 5 0.5-ml i.p. injections, at 8-hr intervals (total 2.5 ml/mouse). One day following the last injection of immune sera, the mice were depleted of T cells by i.p. injection of anti-Thy 1.2 (30H12) at 3-day intervals for 2 wk. Titers of lytic virus in the lungs (A) and titers of lytic virus (B) and latent virus capable of in vitro reactivation (C) in the spleens were subsequently assessed as described in Fig. 1, A T cell help, it has been shown that viral infections can elicit strong T-independent protective Ab responses (44) . Consistent with the data shown here for MHV-68 humoral immunity in CD28 Ϫ/Ϫ mice, T-independent anti-viral responses typically have a short half-life and are non-neutralizing.
It has been shown that EBV latency in the peripheral blood is harbored in resting memory B cells, and it has been suggested that the virus exploits the normal germinal center reaction to gain access to the memory B cell compartment, as a mechanism for maintaining a long-term reservoir of latency in immunocompetent individuals (45) . Our data show that germinal center reactions are not essential for maintaining the reservoir of B cells latently infected with MHV-68, as B cell latency is maintained at normal levels in CD28 Ϫ/Ϫ mice, which are deficient in germinal center reactions. The current data also rule out the possibility that the virus overcomes the requirement for CD28 in germinal center reactions, as we previously suggested (14) . However, it has been shown that memory B cells can be generated and maintained in the absence of germinal center reactions (43) , so further studies will be required to address whether viral latency in memory B cells is a strategy used by the virus to facilitate the maintenance of longterm latency without the necessity for viral reactivation.
Finally, these studies showing the importance of Abs in controlling the persistent stage of MHV-68 infection are consistent with limited data showing a contribution of anti-viral Abs to immune control of persistent EBV, and have important implications for clinical intervention to prevent ␥-herpesvirus reactivation in immunosuppressed patients. An association has been noted between anti-EBV Abs, specifically against EBV-encoded nuclear Ag-1, and posttransplant lymphoproliferative disease (46, 47) . In addition, experimental evidence suggested that Ab transfer reduced the risk of development of EBV-associated lymphoma in SCID mice (48, 49) . Based on the correlation in humans and the experimental data in SCID mice, high-dose i.v. gamma globulin, containing high levels of anti-EBV Abs, has been incorporated into some combined treatment protocols for posttransplant lymphoproliferative disorders following solid organ transplant (48, 50) . However, Ig therapy is not widely used in the prevention and treatment of posttransplant lymphoproliferative syndromes, and only recently have clinical trials been initiated to establish the efficacy of anti-viral Ab therapy (48) . Adoptive T cell immunotherapy has been successful in the prevention of EBV posttransplant lymphoproliferative disease in bone marrow transplants (3), in which the proliferating B cells are usually of donor origin. In solid organ recipients, the proliferating B cells are usually derived from the recipient (51). Thus, Ab-mediated therapy is especially attractive for preventing primary infection or transmission of virus from donor to recipient in EBV-negative transplant recipients. In addition, passive transfer of Abs may provide transient protection during periods of therapeutic immunosuppression.
In conclusion, we have definitively shown that, in the absence of both CD4 ϩ and CD8 ϩ T cells, Ab is sufficient for immune control of a ␥-herpesvirus. These data emphasize the importance of clinical studies to address the ability of high-titered Ig to control ␥-herpesvirus infection in immunocompromised individuals, and support the idea of an EBV vaccine for transplant candidates who lack circulating EBV-specific Abs (48) .
